181 related articles for article (PubMed ID: 20514788)
1. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.
Yentzer BA; Camacho FT; Young T; Fountain JM; Clark AR; Feldman SR
J Drugs Dermatol; 2010 Apr; 9(4):324-9. PubMed ID: 20514788
[TBL] [Abstract][Full Text] [Related]
2. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.
Eichenfield LF; Basu S; Calvarese B; Trancik RJ
Pediatr Dermatol; 2007; 24(3):289-95. PubMed ID: 17542883
[TBL] [Abstract][Full Text] [Related]
3. Self-reported participant experience with desonide hydrogel in the treatment of mild to moderate atopic dermatitis.
Kerney DL; Ford RO; Gotz V
Cutis; 2011 Jul; 88(1 Suppl):18-24. PubMed ID: 21916152
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.
Hebert AA; Cook-Bolden FE; Basu S; Calvarese B; Trancik RJ;
J Drugs Dermatol; 2007 Feb; 6(2):175-81. PubMed ID: 17373176
[TBL] [Abstract][Full Text] [Related]
5. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis.
Krejci-Manwaring J; Tusa MG; Carroll C; Camacho F; Kaur M; Carr D; Fleischer AB; Balkrishnan R; Feldman SR
J Am Acad Dermatol; 2007 Feb; 56(2):211-6. PubMed ID: 17224366
[TBL] [Abstract][Full Text] [Related]
6. The importance of vehicle properties to patients with atopic dermatitis.
Trookman NS; Rizer RL; Ho ET; Ford RO; Gotz V
Cutis; 2011 Jul; 88(1 Suppl):13-7. PubMed ID: 21919229
[TBL] [Abstract][Full Text] [Related]
7. A novel hydrogel vehicle formulated for the treatment of atopic dermatitis.
Kircik L; Del Rosso J
J Drugs Dermatol; 2007 Jul; 6(7):718-22. PubMed ID: 17763596
[TBL] [Abstract][Full Text] [Related]
8. The effect of desonide hydrogel on pruritis associated with atopic dermatitis.
Kircik L
J Drugs Dermatol; 2014 Jun; 13(6):725-8. PubMed ID: 24918564
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
10. Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis.
Yentzer BA; Ade RA; Fountain JM; Clark AR; Taylor SL; Borgerding E; Feldman SR
Cutis; 2010 Oct; 86(4):208-13. PubMed ID: 21140931
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
[TBL] [Abstract][Full Text] [Related]
12. Moisturizing advantages of desonide hydrogel in treating atopic dermatitis.
Trookman NS; Rizer RL; Ho ET; Ford RO; Gotz V
Cutis; 2011 Jul; 88(1 Suppl):7-12. PubMed ID: 21916151
[TBL] [Abstract][Full Text] [Related]
13. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y
J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
[TBL] [Abstract][Full Text] [Related]
15. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis].
Lebrun-Vignes B; Legrain V; Amoric J; Taïeb A
Ann Dermatol Venereol; 2000; 127(6-7):590-5. PubMed ID: 10930856
[TBL] [Abstract][Full Text] [Related]
17. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
[TBL] [Abstract][Full Text] [Related]
18. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
20. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.
Reitamo S; Rustin M; Harper J; Kalimo K; Rubins A; Cambazard F; Brenninkmeijer EE; Smith C; Berth-Jones J; Ruzicka T; Sharpe G; Taieb A;
Br J Dermatol; 2008 Sep; 159(4):942-51. PubMed ID: 18637898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
